Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Immune checkpoint inhibitors and risk of immune-mediated adverse events: a cohort study comparing extended versus standard interval administration ; volume:24 ; number:1 ; day:22 ; month:2 ; year:2024 ; pages:1-10 ; date:12.2024
Clinical and experimental medicine ; 24, Heft 1 (22.2.2024), 1-10, 12.2024
- Creator
-
Lessard-Roy, Amélia
Marchand, Roxanne
Lemieux, Pierre
Masse, Mélanie
Lacerte, Alexandre
Carmichael, Pierre-Hugues
Laurin, Danielle
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10238-024-01301-7
- URN
-
urn:nbn:de:101:1-2502152125407.705208356986
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lessard-Roy, Amélia
- Marchand, Roxanne
- Lemieux, Pierre
- Masse, Mélanie
- Lacerte, Alexandre
- Carmichael, Pierre-Hugues
- Laurin, Danielle
- SpringerLink (Online service)
Other Objects (12)
A Review of Immune-Mediated Adverse Events in Melanoma
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Immune monitoring and treatment in immune-mediated inflammatory diseases
Adaptive immune responses, immune escape and immune-mediated pathogenesis during HDV infection
Immune-mediated neurological complications and dengue
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Management of Immune-Mediated Paraneoplastic Neurological Disorders
Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia
Immune-Mediated Coagulopathy in COVID-19 Infection
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
A Review of Immune-Mediated Adverse Events in Melanoma
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Immune monitoring and treatment in immune-mediated inflammatory diseases
Adaptive immune responses, immune escape and immune-mediated pathogenesis during HDV infection
Immune-mediated neurological complications and dengue
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Management of Immune-Mediated Paraneoplastic Neurological Disorders
Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia
Immune-Mediated Coagulopathy in COVID-19 Infection
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
A Review of Immune-Mediated Adverse Events in Melanoma
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Immune monitoring and treatment in immune-mediated inflammatory diseases
Adaptive immune responses, immune escape and immune-mediated pathogenesis during HDV infection
Immune-mediated neurological complications and dengue
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Management of Immune-Mediated Paraneoplastic Neurological Disorders
Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia
Immune-Mediated Coagulopathy in COVID-19 Infection